Nonetheless, beyond 10 years the rate of lymphoma-associated death even in this rituximab-treated subgroup increased if prevalent nonsynonymous BCL2 mutations were present at diagnosis (Figs. 3B and S5). Here, BCL2 is linked to lymphoma.